Literature DB >> 23063260

Mortality rate and gross pathology due to tuberculosis in wild brushtail possums (Trichosurus vulpecula) following low dose subcutaneous injection of Mycobacterium bovis.

Graham Nugent1, Ivor Yockney, Jackie Whitford, Martin L Cross.   

Abstract

Gross pathology due to tuberculosis can be established experimentally in brushtail possums (Trichosurus vulpecula) within 7 weeks of injection of virulent Mycobacterium bovis into subcutaneous connective tissues of the peripheral limbs. This pathology involves lymphadenomegaly and development of gross lesions in peripheral lymph nodes, with subsequent gross lesions in the lungs and reticuloendothelial organs. Using this artificial infection model, we here assessed the mortality rate for possums in the wild, to provide new information on the likely survival period for New Zealand's major wildlife host. Possums were trapped and inoculated with <50 CFU of M. bovis, then fitted with mortality signal emitting radio tracking collars, released and re-tracked for 6 months. Possum survival probability was 89% up to 12 weeks post-injection (p.i.), but cumulative mortality was rapid from then on. The median survival period, based on study of 38 possums, was 18 weeks p.i.; this corresponds with a predicted time interval of 11 weeks between first presentation of TB as palpable lymphadenomegaly and death for an average possum, shorter than period values currently used in possum TB epidemiological modelling. We also examined gross pathology in 11 possums by post mortem necropsy, and confirmed lymphadenomegaly and tuberculous lesions at 7 and 12 weeks p.i. Extra-peripheral gross lesions were more frequent among possums at 12 weeks p.i. than at 7 weeks, while the occurrence of lung lesions (the most likely cause of disease-induced mortality) was apparent in animals at 12 weeks but not at 7 weeks p.i. Our results suggest that the time course of TB from development of gross lesions to mortality may be shorter than previously estimated from field studies of naturally tuberculous possums.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23063260     DOI: 10.1016/j.prevetmed.2012.09.008

Source DB:  PubMed          Journal:  Prev Vet Med        ISSN: 0167-5877            Impact factor:   2.670


  6 in total

1.  Quantifying short-term foraging movements in a marsupial pest to improve targeted lethal control and disease surveillance.

Authors:  Ivor J Yockney; M Cecilia Latham; Carlos Rouco; Martin L Cross; Graham Nugent
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

Review 2.  Toward eradication: the effect of Mycobacterium bovis infection in wildlife on the evolution and future direction of bovine tuberculosis management in New Zealand.

Authors:  P G Livingstone; N Hancox; G Nugent; G W de Lisle
Journal:  N Z Vet J       Date:  2015-03-23       Impact factor: 1.628

3.  Development of integrated surveillance systems for the management of tuberculosis in New Zealand wildlife.

Authors:  D P Anderson; D S L Ramsey; G W de Lisle; M Bosson; M L Cross; G Nugent
Journal:  N Z Vet J       Date:  2015-03-12       Impact factor: 1.628

4.  Assessing Movements of Brushtail Possums (Trichosurus vulpecula) in Relation to Depopulated Buffer Zones for the Management of Wildlife Tuberculosis in New Zealand.

Authors:  Andrea E Byrom; Dean P Anderson; Morgan Coleman; Caroline Thomson; Martin L Cross; Roger P Pech
Journal:  PLoS One       Date:  2015-12-21       Impact factor: 3.240

5.  Field Trial of an Aerially-Distributed Tuberculosis Vaccine in a Low-Density Wildlife Population of Brushtail Possums (Trichosurus vulpecula).

Authors:  Graham Nugent; Ivor J Yockney; E Jackie Whitford; Martin L Cross; Frank E Aldwell; Bryce M Buddle
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

Review 6.  Roll-Back Eradication of Bovine Tuberculosis (TB) From Wildlife in New Zealand: Concepts, Evolving Approaches, and Progress.

Authors:  Graham Nugent; Andrew M Gormley; Dean P Anderson; Kevin Crews
Journal:  Front Vet Sci       Date:  2018-11-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.